GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (NYSE:MRK) » Definitions » Cyclically Adjusted PS Ratio

Merck (MRK) Cyclically Adjusted PS Ratio : 6.55 (As of Apr. 27, 2024)


View and export this data going back to 1949. Start your Free Trial

What is Merck Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Merck's current share price is $131.20. Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $20.04. Merck's Cyclically Adjusted PS Ratio for today is 6.55.

The historical rank and industry rank for Merck's Cyclically Adjusted PS Ratio or its related term are showing as below:

MRK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.17   Med: 4.31   Max: 6.58
Current: 6.55

During the past years, Merck's highest Cyclically Adjusted PS Ratio was 6.58. The lowest was 3.17. And the median was 4.31.

MRK's Cyclically Adjusted PS Ratio is ranked worse than
87.5% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs MRK: 6.55

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Merck's adjusted revenue per share data for the three months ended in Dec. 2023 was $5.758. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $20.04 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Merck Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Merck's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Cyclically Adjusted PS Ratio Chart

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.39 4.79 4.39 5.85 5.44

Merck Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.48 5.85 5.14 5.44 -

Competitive Comparison of Merck's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted PS Ratio falls into.



Merck Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Merck's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=131.20/20.04
=6.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Merck's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=5.758/129.4194*129.4194
=5.758

Current CPI (Dec. 2023) = 129.4194.

Merck Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 3.455 99.695 4.485
201406 3.708 100.560 4.772
201409 3.627 100.428 4.674
201412 3.632 99.070 4.745
201503 3.290 99.621 4.274
201506 3.433 100.684 4.413
201509 3.552 100.392 4.579
201512 3.630 99.792 4.708
201603 3.332 100.470 4.292
201606 3.530 101.688 4.493
201609 3.782 101.861 4.805
201612 3.645 101.863 4.631
201703 3.411 102.862 4.292
201706 3.608 103.349 4.518
201709 3.786 104.136 4.705
201712 3.822 104.011 4.756
201803 3.704 105.290 4.553
201806 3.882 106.317 4.726
201809 4.031 106.507 4.898
201812 4.175 105.998 5.098
201903 4.155 107.251 5.014
201906 4.544 108.070 5.442
201909 4.820 108.329 5.758
201912 1.621 108.420 1.935
202003 4.734 108.902 5.626
202006 3.688 108.767 4.388
202009 4.306 109.815 5.075
202012 4.309 109.897 5.074
202103 4.182 111.754 4.843
202106 4.489 114.631 5.068
202109 5.187 115.734 5.800
202112 5.334 117.630 5.869
202203 6.268 121.301 6.688
202206 5.745 125.017 5.947
202209 5.885 125.227 6.082
202212 5.428 125.222 5.610
202303 5.679 127.348 5.771
202306 5.922 128.729 5.954
202309 6.269 129.860 6.248
202312 5.758 129.419 5.758

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merck  (NYSE:MRK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Merck Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Merck's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (MRK) Business Description

Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Executives
Johannes Jacobus Oosthuizen officer: SVP, U.S. Market 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Richard R. Deluca officer: EVP&Pres, Merck Animal Heallth 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steven Mizell officer: EVP,Human Resources 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Joseph Romanelli officer: President, Human Health Int?l 126 EAST LINCOLN AVENUE, RAHWAY NJ 07065
Rita A Karachun officer: Sr. VP Fince-Global Controller 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jennifer Zachary officer: EVP, General Counsel 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Michael Williams officer: EVP,Chief Info&Digital Officer MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Robert M Davis officer: Evp, Global Svcs & CFO 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sanat Chattopadhyay officer: Exe V-P & Pres. MMD 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kenneth C Frazier officer: Chairman, President & CEO 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Chirfi Guindo officer: Chief Marketing Officer C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Baker Douglas M Jr director 370 WBASHA ST NORTH, ST PAUL MN 55102
Arpa Garay officer: SVP Human Health Global Mktg. 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Caroline Litchfield officer: EVP & CFO 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Julie L. Gerberding officer: EVP Strat Comm, GI Pub Policy 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033

Merck (MRK) Headlines

From GuruFocus

Q3 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at Citi BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at ASCO Annual Meeting Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at UBS BioPharma Conference Transcript

By GuruFocus Research 01-23-2024